|
Oral Collagen for Rheumatoid Arthritis Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Oral Collagen for Rheumatoid Arthritis conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Oral Collagen for Rheumatoid Arthritis Clinical research trials and Oral Collagen for Rheumatoid Arthritis healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Oral Collagen for Rheumatoid Arthritis. Oral Collagen for Rheumatoid Arthritis Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Oral Collagen for Rheumatoid Arthritis clinical trial. Subjects frequently obtain the most expert healthcare possible for their Oral Collagen for Rheumatoid Arthritis condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "O" Clinical Trials Conditions > Oral Collagen for Rheumatoid Arthritis  Oral Collagen for Rheumatoid Arthritis
Oral Collagen for Rheumatoid Arthritis
For Condition: Rheumatoid Arthritis
Status: No longer recruiting
Sponsor(s): National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) ,
Synopsis: Rheumatoid arthritis (RA) is an autoimmune disease characterized by swelling and inflammation of the joints. In RA, the immune system attacks a person's own cells inside joints, eventually leading to joint damage and disability. This study will determine if oral bovine type II collagen (bovine CII) will lead to decreased joint inflammation in RA patients.
Details: RA is an inflammatory disease that causes pain, swelling, stiffness, and loss of function in the joints. The study will evaluate the effects of using oral bovine CII on RA patients by assessing the levels of inflammation markers such as interferon gamma (IFN-gamma), interleukin-10 (IL-10), and transforming growth factor beta (TGF-beta). This study is a multicenter clinical trial to be conducted at the University of Tennessee, Memphis (the lead center) and the West Tennessee Medical Specialty Clinic (a collaborating site). Patients enrolled will be allowed to continue a constant dose of disease-modifying anti-rheumatic drugs (DMARDs) and prednisone less than or equal to 7.5 mg/day. Patients will be randomly assigned to one of two groups. The low dose group will receive 30 mcg daily for 10 weeks, then 50 mcg daily for 10 weeks, followed by 70 mcg daily for 10 more weeks; the high dose group will receive 90 mcg daily for 10 weeks, then 100 mcg daily for 10 weeks, followed by 130 mcg daily for 10 more weeks. Blood will be collected at screening and at Weeks 10, 20, and 30. Blood will be analyzed for indicators of inflammation. Note: this trial is no longer being conducted as an intervention trial. Accrual has been discontinued, although patients previously enrolled are still being followed.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label, Dose Comparison, Parallel Assignment, Efficacy Study
Minimum Age/Maximum Age: 18 Years/80 Years
Genders: Both
Protocol Entry Criteria: Note: accrual into this trial has been discontinued, but patients previously enrolled are still being followed. Inclusion Criteria: - Clinically stable RA and unlikely to require adjustment of doses of DMARDs, NSAIDs, prednisone, or anti-TNFα therapies for the treatment phase of the study - Meets American College of Rheumatology (ACR) 1988 revised criteria for RA - Onset of disease at age 16 or older - Onset of disease at least 3 months prior to enrollment - PBMC – IFNγ – α1(II)/PBS stimulation index greater than or equal to 1.5 in 6 months prior to baseline visit - Agree to discontinue herbal remedies described in this protocol - Agree to use acceptable forms of contraception Exclusion Criteria: - Participation in another clinical research study involving the evaluation of another investigational drug within 90 days prior to study entry - Currently taking greater than 7.5 mg prednisone daily - Intra-articular corticosteroid injections within 30 days prior to study entry - Concurrent serious medical condition which, in the opinion of the investigator, makes the patient inappropriate for the study - Pregnancy - Beef allergy - Use of fish oil within 4 weeks of study entry - Previous use of auranofin or cyclophosphamide (all other DMARDs are allowed) - Previous autologous or heterologous stem cell transplantation - Active malignancy or past treatment consisting of antineoplastic drugs or total lymphoid irradiation - Intolerance to citrus juices or colorless carbonated beverages
Total Enrollment: 110
Location and Contact Information:
Overall Study Official:
ArnoldPostlethwaite, Principal Investigator, University of Tennessee at Memphis Department of Medicine
University of Tennessee, Memphis
Memphis, Tennessee, 38163
United States
The Arthritis Clinic of Jackson, PLLC
Jackson, Tennessee, 38301
United States
Additional Information:
Study ID Numbers: NIAMS-037; R01 AR45255
Study Start Date: July 1999
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000401
Other Rheumatoid Arthritis Studies:
1. The Role of Cytokines on Growth Hormone Suppression in Premenopausal Women with Rheumatoid Arthritis and the Effect of Treatment with Etanercept
2. Patient Education in Rheumatoid Arthritis and Osteoarthritis
3. Trial with HuMax-CD4 in Patients with Rheumatoid Arthritis failing treatment with Methotrexate and a TNF-alpha blocker.
4. Antifolate Effectiveness in Arthritis
5. Safety and efficacy of a monoclonal antibody for treatment of rheumatoid arthritis.
Related Studies:
Other Rheumatoid Arthritis Clinical Trials
Other Tennessee Clinical Trials
Other Jackson Clinical Trials
Oral Collagen for Rheumatoid Arthritis
|
|
|
|
|
|
|
|
